Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3 ...

Perioperative therapy has become a critical component in the management of resectable non–small cell lung cancer (NSCLC), particularly in the era of precision medicine. Although molecular testing is ...

Evolution of CAR technology: from conventional CAR-T cells to diverse cellular platforms and clinical applications. An ...

Chinese hamster ovary (CHO) cell lines are one of the most-used cell-based protein expression systems for therapeutics, thanks to their ability to support post-translational modifications such as ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...

Researchers have built a platform that programs short DNA fragments inside living cells to control protein activity, all ...